Chemistry:Vixotrigine
 | |
| Clinical data | |
|---|---|
| Other names | Raxatrigine; CNV1014802; GSK-1014802; BIIB 074 |
| Routes of administration | By mouth |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H19FN2O2 |
| Molar mass | 314.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[citation needed] Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker.[citation needed] As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]
See also
References
- ↑ "CNV1014802". Convergence Pharmaceuticals. http://www.convergencepharma.com/index.asp?page_id=14.
- ↑ Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. 1 March 2013. p. 508. ISBN 978-0-7020-5374-0. https://books.google.com/books?id=ok0_jIJ0w_wC&pg=PA508.
- ↑ "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–3699. August 2014. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
- ↑ 4.0 4.1 "Vixotrigine - Biogen". Adis Insight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800027679.
External links
 |  |
